Janssen Presents First Data from MajesTEC-2 Trial of

Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The...

Related Keywords

United States ,Belgium ,Beerse ,Region Flamande ,American ,Emma Searle ,Sen Zhuang ,Edmond Chan ,American Society Of Clinical Oncology ,International Myeloma Working Group ,Janssen Biotech Inc ,Janssen Research Development ,Janssen Pharmaceutical Companies ,American Society For Transplantation ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,Clinical Research ,Committee For Medicinal Products Human Use ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,University Of Manchester ,European Commission ,Exchange Commission ,American Society Of Hematology Meeting ,Companies Of Johnson ,European Commission Grants Marketing Authorisation ,European Medicines Agency ,Johnson ,Initial Phase ,Annual Meeting ,New Orleans ,Consultant Haematologist ,Honorary Senior Lecturer ,Christie Hospital ,Area Lead Haematology ,Evaluating Teclistamabin Relapsed ,Refractory Multiple Myeloma ,Vice President ,Janssen Research ,Common Terminology Criteria ,Adverse Events ,American Society ,Cellular Therapy ,Medicinal Products ,Human Use ,Product Characteristics ,Janssen Biotech ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Subcutaneous Daratumumab ,Multiple Myeloma ,One Cohort ,Hematology Meeting ,Participants With Multiple Myeloma ,Compare Teclistamab ,Combination With Daratumumab ,B Cell Maturation Antigen ,Correlative Analyses ,Participants With Relapsed ,Cytokine Release Syndrome Using ,Physiologically Based Pharmacokinetic Model ,Case Study ,Population Pharmacokinetics ,Exposure Response Relationship Support ,Refractory Multiple ,Escalation Study ,Subcutaneous Daratumumab Regimens ,Bispecifict Cell Redirection Antibodies ,Daratumumab Subcutaneously ,Versus Daratumumab ,Commission Grants Marketing Authorisation ,Subcutaneous Formulation ,Dexamethasone Versus Bortezomib ,Patients With Previously Treated Multiple Myeloma ,Three Year Follow Up ,Lymphoma Myeloma ,Today Population Factsheets ,Janssen Emea ,